Institutional Ownership
Bioline Rx Limited
CUSIP 09071M304SPONSORED ADRBLRXQ1 2026
13D / 13G Filings
1
Schedule 13D/13G on record
Beneficial Filers
1
Distinct reporting persons
Largest Stake
7.2%
Max % of class reported
Institutional Holders
12
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
1 filings · latest Aug 14, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Aug 14, 2025 | Highbridge Capital Management, LLC | 13G | 7.2% | 172.95M | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Xtx Topco Ltd | 10.9K | $25.3K |
| 2 | Rhumbline Advisers | 2.4K | $5.4K |
| 3 | Bnp Paribas Financial Markets | 1.8K | $4.1K |
| 4 | Wells Fargo & Company/Mn | 1.8K | $4.0K |
| 5 | Citigroup Inc | 1.7K | $4.0K |
| 6 | Ubs Group AG | 529 | $1.2K |
| 7 | Nemes Rush Group LLC | 250 | $575 |
| 8 | Morgan Stanley | 100 | $230 |
| 9 | Osaic Holdings, Inc. | 26 | $59 |
| 10 | Rockefeller Capital Management L.P. | 12 | $28 |